191 related articles for article (PubMed ID: 19861443)
1. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
Friedman DR; Weinberg JB; Barry WT; Goodman BK; Volkheimer AD; Bond KM; Chen Y; Jiang N; Moore JO; Gockerman JP; Diehl LF; Decastro CM; Potti A; Nevins JR
Clin Cancer Res; 2009 Nov; 15(22):6947-55. PubMed ID: 19861443
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
3. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
6. Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Dillman RO; Schreeder MT; Hon JK; Connelly EF; DePriest C; Cutter K
Cancer Biother Radiopharm; 2007 Apr; 22(2):185-93. PubMed ID: 17600465
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
9. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.
Winkler D; Döhner H; Stilgenbauer S
Curr Drug Targets; 2006 Oct; 7(10):1313-27. PubMed ID: 17073593
[TBL] [Abstract][Full Text] [Related]
10. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
12. [News in therapeutic management of chronic lymphoid leukemia].
Michallet AS; Salles G; Coiffier B; Michallet M
Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
[TBL] [Abstract][Full Text] [Related]
13. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saberi Hosnijeh F; van der Straten L; Kater AP; van Oers MHJ; Posthuma WFM; Chamuleau MED; Bellido M; Doorduijn JK; van Gelder M; Hoogendoorn M; de Boer F; Te Raa GD; Kerst JM; Marijt EWA; Raymakers RAP; Koene HR; Schaafsma MR; Dobber JA; Tonino SH; Kersting SS; Langerak AW; Levin MD
Exp Hematol; 2020 Sep; 89():55-60.e6. PubMed ID: 32781097
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatments for chronic lymphocytic leukaemia.
Robak T; Jamroziak K; Robak P
Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
[TBL] [Abstract][Full Text] [Related]
15. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
Kay NE; LaPlant BR; Pettinger AM; Call TG; Leis JF; Ding W; Parikh SA; Conte MJ; Bowen DA; Shanafelt TD
Expert Rev Hematol; 2018 Apr; 11(4):337-349. PubMed ID: 29460654
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
Shanafelt TD; Byrd JC; LaPLant B; Zent CS; Call T; Secreto C; Grever MR; Lin TS; Kay NE
Br J Haematol; 2009 Sep; 146(6):660-4. PubMed ID: 19604237
[TBL] [Abstract][Full Text] [Related]
17. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
18. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.
Nørgaard CH; Jakobsen LH; Gentles AJ; Dybkær K; El-Galaly TC; Bødker JS; Schmitz A; Johansen P; Herold T; Spiekermann K; Brown JR; Klitgaard JL; Johnsen HE; Bøgsted M
PLoS One; 2018; 13(3):e0193249. PubMed ID: 29513759
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
20. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
